Copy to clipboard 
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for First Quarter 2026
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,552.8 | $4,318.3 | $234.5 | 5.4% |
| Knees | $2,226.9 | $2,124.6 | $102.3 | 4.8% |
| Hips | $1,671.9 | $1,581.9 | $90.0 | 5.7% |
| Extremities | $654.1 | $611.8 | $42.3 | 6.9% |
| Spine | $1,115.5 | $1,180.8 | ($65.3) | (5.5%) |
| Trauma | $2,082.1 | $1,872.0 | $210.2 | 11.2% |
| Sports Medicine | $1,107.7 | $1,005.7 | $102.0 | 10.1% |
| Orthobiologics | $432.7 | $417.3 | $15.4 | 3.7% |
| Enabling Technology | $244.1 | $226.0 | $18.1 | 8% |
| Other | $1,142.5 | $977.1 | $165.5 | 16.9% |
| Total | $10,677.5 | $9,997.1 | $680.4 | 6.8% |
Total Orthopedic Sales for Reporting Companies
| Company | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $28.0 | $24.6 | $3.4 | 13.8% |
| ATEC | $192.1 | $169.2 | $22.9 | 13.6% |
| Bioventus | $118.9 | $111.0 | $7.9 | 7.1% |
| BONESUPPORT | $35.6 | $31.2 | $4.5 | 14.3% |
| Carlsmed | $16.1 | $10.2 | $5.9 | 58.2% |
| CONMED | $147.7 | $138.3 | $9.4 | 6.8% |
| J&J MedTech | $2,383.3 | $2,241.2 | $142.2 | 6.3% |
| Enovis | $317.1 | $286.3 | $30.9 | 10.8% |
| Globus Medical | $759.9 | $598.1 | $161.7 | 27% |
| Orthofix | $196.7 | $193.6 | $3.1 | 1.6% |
| OrthoPediatrics | $48.5 | $42.8 | $5.7 | 13.4% |
| Shoulder Innovations | $16.7 | $10.1 | $6.6 | 64.9% |
| SI-BONE | $52.6 | $47.3 | $5.3 | 11.2% |
| Smith+Nephew | $1,042.5 | $971.4 | $71.1 | 7.3% |
| Stryker | $3,131.4 | $3,113.9 | $17.6 | 0.6% |
| Treace Medical | $47.2 | $52.6 | ($5.4) | (10.2%) |
| Vericel | $56.4 | $46.3 | $10.1 | 21.8% |
| Zimmer Biomet | $2,086.7 | $1,909.1 | $177.5 | 9.3% |
Earnings Call Highlights for First Quarter 2026
CONMED Sees BioBrace as Long-Term Growth Driver
BioBrace is a key driver for CONMED’s long range growth and a core pillar of its sports medicine strategy. As more surgeons adopt the implant, the company is seeing broader utilization across primary repairs and more complex cases.
DePuy Synthes Completes Operationally Solid First Quarter
DePuy Synthes’ growth was driven by new product introductions, offset by competitive pressure and inventory dynamics in its Sports, Spine, and Other segments. It experienced minor procedure softness during the quarter due to disruptive weather in the U.S., but otherwise called the quarter “seasonally softer but operationally solid.”
Orthofix Expects Improvement Throughout 2026
Excluding sales from the discontinued M6 line, the company’s spine business grew nearly 6%. The top 30 distributors grew their sales 27% in the first quarter compared to the prior year’s first quarter. In trauma, Orthofix sunset about 30 product lines in 2025 in its transition to focus on complex limb reconstruction. Additionally, timing of its OSCAR capital sales offset some gains in the U.S.
Smith+Nephew Delivers Strong Quarter Despite Knee Softness
U.S. knee performance was weaker than expected as the company made deliberate trade-offs to balance set deployment and efficiency ahead of the launch of its kinematic knee system LANDMARK, which is expected to make the portfolio more competitive as the market moves toward cementless.
Stryker Expects Hack Impact to Normalize Over Course of Year
Given the consignment nature of orthopedic implants, the hack primarily disrupted Stryker’s revenue recognition timing for its orthopedic businesses. Company CEO Kevin Lobo said he didn’t expect to lose customers over the disruption, and that Stryker may have emerged with an even stronger reputation given its resilience and response.
Zimmer Biomet Transformation Off to Strong Start in 2026
In terms of specialization, the company plans to add over 200 robotic clinical reps by the end of 2027 to support its diverse array of technologies. Zimmer Biomet completed enrollment in a 102-patient clinical study for its Mbos system acquired from Monogram, and expects to launch a semi-autonomous version in early 2027 followed by a fully autonomous version in late 2027/early 2028.
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for First Quarter 2026
Where applicable, company names...
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for First Quarter 2026
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,552.8 | $4,318.3 | $234.5 | 5.4% |
| Knees | $2,226.9 | $2,124.6 | $102.3 | 4.8% |
| Hips | $1,671.9 | $1,581.9 | $90.0 | 5.7% |
| Extremities | $654.1 | $611.8 | $42.3 | 6.9% |
| Spine | $1,115.5 | $1,180.8 | ($65.3) | (5.5%) |
| Trauma | $2,082.1 | $1,872.0 | $210.2 | 11.2% |
| Sports Medicine | $1,107.7 | $1,005.7 | $102.0 | 10.1% |
| Orthobiologics | $432.7 | $417.3 | $15.4 | 3.7% |
| Enabling Technology | $244.1 | $226.0 | $18.1 | 8% |
| Other | $1,142.5 | $977.1 | $165.5 | 16.9% |
| Total | $10,677.5 | $9,997.1 | $680.4 | 6.8% |
Total Orthopedic Sales for Reporting Companies
| Company | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $28.0 | $24.6 | $3.4 | 13.8% |
| ATEC | $192.1 | $169.2 | $22.9 | 13.6% |
| Bioventus | $118.9 | $111.0 | $7.9 | 7.1% |
| BONESUPPORT | $35.6 | $31.2 | $4.5 | 14.3% |
| Carlsmed | $16.1 | $10.2 | $5.9 | 58.2% |
| CONMED | $147.7 | $138.3 | $9.4 | 6.8% |
| J&J MedTech | $2,383.3 | $2,241.2 | $142.2 | 6.3% |
| Enovis | $317.1 | $286.3 | $30.9 | 10.8% |
| Globus Medical | $759.9 | $598.1 | $161.7 | 27% |
| Orthofix | $196.7 | $193.6 | $3.1 | 1.6% |
| OrthoPediatrics | $48.5 | $42.8 | $5.7 | 13.4% |
| Shoulder Innovations | $16.7 | $10.1 | $6.6 | 64.9% |
| SI-BONE | $52.6 | $47.3 | $5.3 | 11.2% |
| Smith+Nephew | $1,042.5 | $971.4 | $71.1 | 7.3% |
| Stryker | $3,131.4 | $3,113.9 | $17.6 | 0.6% |
| Treace Medical | $47.2 | $52.6 | ($5.4) | (10.2%) |
| Vericel | $56.4 | $46.3 | $10.1 | 21.8% |
| Zimmer Biomet | $2,086.7 | $1,909.1 | $177.5 | 9.3% |
Earnings Call Highlights for First Quarter 2026
CONMED Sees BioBrace as Long-Term Growth Driver
BioBrace is a key driver for CONMED’s long range growth and a core pillar of its sports medicine strategy. As more surgeons adopt the implant, the company is seeing broader utilization across primary repairs and more complex cases.
DePuy Synthes Completes Operationally Solid First Quarter
DePuy Synthes’ growth was driven by new product introductions, offset by competitive pressure and inventory dynamics in its Sports, Spine, and Other segments. It experienced minor procedure softness during the quarter due to disruptive weather in the U.S., but otherwise called the quarter “seasonally softer but operationally solid.”
Orthofix Expects Improvement Throughout 2026
Excluding sales from the discontinued M6 line, the company’s spine business grew nearly 6%. The top 30 distributors grew their sales 27% in the first quarter compared to the prior year’s first quarter. In trauma, Orthofix sunset about 30 product lines in 2025 in its transition to focus on complex limb reconstruction. Additionally, timing of its OSCAR capital sales offset some gains in the U.S.
Smith+Nephew Delivers Strong Quarter Despite Knee Softness
U.S. knee performance was weaker than expected as the company made deliberate trade-offs to balance set deployment and efficiency ahead of the launch of its kinematic knee system LANDMARK, which is expected to make the portfolio more competitive as the market moves toward cementless.
Stryker Expects Hack Impact to Normalize Over Course of Year
Given the consignment nature of orthopedic implants, the hack primarily disrupted Stryker’s revenue recognition timing for its orthopedic businesses. Company CEO Kevin Lobo said he didn’t expect to lose customers over the disruption, and that Stryker may have emerged with an even stronger reputation given its resilience and response.
Zimmer Biomet Transformation Off to Strong Start in 2026
In terms of specialization, the company plans to add over 200 robotic clinical reps by the end of 2027 to support its diverse array of technologies. Zimmer Biomet completed enrollment in a 102-patient clinical study for its Mbos system acquired from Monogram, and expects to launch a semi-autonomous version in early 2027 followed by a fully autonomous version in late 2027/early 2028.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
